Filter by year

Filter by topic

Abzena announces appointment of Petra Dieterich as Scientific Lead

Abzena, the leading Partner Research Organization (PRO) providing integrated discovery, development and manufacturing of biologics and antibody drug conjugates (ADCs), has announced the appointment of Dr. Petra Dieterich, DPhil, MBA, as scientific lead. Reporting to Abzena’s chief technology officer Dr. Louise Duffy, Dr. Dieterich will use her extensive technical knowledge and leadership experience to support […] Read more

Abzena Opens a New Biologics Testing Lab to Support Partners Programs

Abzena, a leading Partner Research Organization (PRO) providing integrated discovery, development and manufacturing of biologics and antibody drug conjugates (ADCs), today announced the opening of a new Biologics Testing Laboratory situated in close proximity to Abzena’s Biologics process development and manufacturing hub in San Diego, California. This brand-new facility will give Abzena’s partners access to […] Read more

Abzena Secures $65 Million in Additional Funding to Accelerate Growth and Expand Capacity

Investment from Welsh, Carson, Anderson & Stowe and Biospring Partners allows Abzena to expand manufacturing facilities for biologic drug substance, fill finish, and to open a biologic testing laboratory.  San Diego, CA (March 31, 2022) – Abzena, a leading global contract development and manufacturing organization (CDMO) providing integrated discovery, development, and manufacturing of biologics and […] Read more

Abzena, Alira Health and Oncodesign launch DRIVETM-Biologics to support access to specialist services from discovery to clinical development for oncology and inflammation

Consortium provides a unique integrated solution with specialist services, from biologics discovery to clinical and commercial manufacturing   Cambridge, UK, Framingham, MA (USA),  and Dijon, France, February 24, 2022 – Abzena, a partner research organization for integrated services from discovery through to clinical and commercial manufacturing for biologics and bioconjugates, Alira Health, an international patient-centric […] Read more

Abzena appoints Kevin Lundquist as Chief Financial Officer

Cambridge, UK and San Diego, CA, February 1, 2022 – Abzena, a leading Partner Research Organization (PRO) for biopharmaceutical outsourced solutions from concept to clinic and into GMP manufacturing has announced the appointment of Kevin Lundquist as Chief Financial Officer, effective January 31, 2022. Richard Milbank, our former Chief Financial Officer, will advise and remain with […] Read more

Abzena appoints Jim Kennamer as SVP and Site Head of North Carolina

 Cambridge, UK and San Diego, CA, January 20, 2022 – Abzena, a leading Partner Research Organization (PRO) for biopharmaceutical outsourced solutions from concept to clinic and into GMP manufacturing has announced the appointment of Jim Kennamer as Senior Vice President and Site Head of North Carolina. Jim has a Bachelor of Science Degree in Biochemistry from […] Read more

Abzena Promotes Troy Wright to Senior Vice President and Global Head of Quality

Cambridge, UK and San Diego, CA, 15 December 2021 – Abzena, the leading Partner Research Organization (PRO) for outsourced solutions integrating gene to commercial for large molecules and bioconjugates, announced it has promoted Troy Wright to Senior Vice President and Global Head of Quality.  Reporting to Jonathan Goldman MD, CEO, Mr. Wright will be accountable for Abzena’s […] Read more

Abzena Promotes Dr. Louise Duffy as Chief Technical Officer

Cambridge, UK and San Diego, CA, 26 October 2021 – Abzena, the leading Partner Research Organization (PRO) for outsourced solutions integrating gene to commercial for large molecules and bioconjugates, announced it has promoted Dr. Louise Duffy as Chief Technical Officer. Reporting to Kimball Hall, President and Chief Operating Officer, and complimenting the operational and technical leadership team, […] Read more

Abzena and evitria announce partnership to provide best in class lead candidate selection.

Abzena, a Partner Research Organization for integrated discovery to GMP solutions for biologics and bioconjugates, and evitria AG, a best-in-class transient antibody expression service provider have announced their partnership to enhance lead candidate selection for large molecules. This collaboration will leverage evitria’s world-class reputation in rapid transient production of antibodies alongside Abzena’s lead candidate design and developability expertise underpinned by a comprehensive range […] Read more

Abzena and BioXpress Therapeutics announce partnership to support the development and manufacture of biosimilars for global customers.

Abzena, a Global Partner Research Organization for integrated bench to patient solutions for biologics and bioconjugates, and BioXpress Therapeutics, a world-class leading developer of high quality, monoclonal antibody (mAb) biosimilar therapeutics have announced their partnership to support biosimilar development for third party customers. The partnership creates an integrated solution between two leading service providers with expertise in biosimilar development and GMP manufacture.  The partnership will […] Read more

Interested in our services? Get In Touch